The insider selling is immaterial relative to market cap and likely liquidity-driven. Monitor for any upcoming earnings or pipeline catalysts (e.g., FDA decisions on ZORYVE) that could drive the stock, but this cluster provides no actionable signal.
Price Chart
Executive Summary
Two insiders at Arcutis Biotherapeutics sold a combined $299K in open-market sales over a week, with Director Welgus Howard G. also exercising multiple derivative options for cash and non-cash transactions. The total sales represent approximately 0.009% of the company's $3.3B market cap, making the cluster trivial in size and unlikely to reflect material negative information. The sales are likely routine liquidity events, especially given the concurrent option exercises and the company's strong analyst consensus (86% bullish). Historical calibration shows prior neutral reports on ARQT have performed well, supporting a low-impact neutral read here.
Key Financial Metrics
Key Facts
- Two insiders sold a total of $299K in open-market sales (0.009% of $3.3B market cap)
- Director Welgus Howard G. exercised multiple derivative options (cash and non-cash) on the same day as his sale
- Patrick Burnett sold 6.7K shares for $175K on 2026-08-12
- Welgus Howard G. sold 4.7K shares for $124K on 2026-08-17
- Total insider activity in the last 30 days is $299K in sells, with no buys
- Analyst consensus is 86% bullish (12 Buy, 2 Hold, 0 Sell)
- Prior neutral reports on ARQT have a 71% win rate at T+20 with +4.98% avg return
Financial Impact
Insider sales of $299K represent 0.009% of market cap — trivial and routine
Risk Factors
- Insider sales, while small, could be followed by larger sales if insiders have more information
- No insider buying to offset the selling signal
- Biotech sector risk: any negative pipeline news could amplify concerns
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-ARQT-1787173284966 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 24, 2026 5w ago | Insider Cluster | $24.86 $26.38 | ▲ +6.11% | ▲ +5.87% | $25.16 (+1.21%) |
Aug 21, 2026 6w ago | Insider Cluster | $25.08 $25.96 | ▲ +3.51% | ▲ +4.04% | $25.16 (+0.32%) |
Aug 19, 2026 6w ago | Insider Cluster | $25.35 $25.38 | ▲ +0.12% | ▲ +0.12% | $25.16 (−0.75%) |
Aug 11, 2026 7w ago | 144 | $26.28 $23.38 | ▼ −11.04% | ▼ −9.14% | $25.16 (−4.26%) |
Aug 6, 2026 8w ago | Insider Cluster | $26.43 $23.66 | ▼ −10.48% | ▼ −11.08% | $25.16 (−4.81%) |
Aug 5, 2026 8w ago | Press Release | $26.43 $23.66 | ▼ −10.48% | ▼ −11.08% | $25.16 (−4.81%) |
Aug 3, 2026 8w ago | 144 | $26.03 $23.75 | ▼ −8.76% | ▼ −7.52% | $25.16 (−3.34%) |
Jun 29, 2026 13w ago | Press Release | $26.22 $27.84 | ▲ +6.18% | ▲ +7.21% | $25.16 (−4.04%) |
Jun 18, 2026 15w ago | Insider Cluster | $26.21 $27.74 | ▲ +5.84% | ▲ +5.30% | $25.16 (−4.01%) |
Jun 9, 2026 16w ago | 8-K | $23.23 $28.78 | ▲ +23.89% | ▲ +20.27% | $25.16 (+8.31%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access